Botulinum toxin in essential hand tremor - A randomized double-blind placebo-controlled study with customized injection approach

Shivam Om Mittal, Duarte Machado, Diana Richardson, Divyanshu Dubey, Bahman Jabbari

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Introduction: To evaluate the safety and efficacy of incobotulinumtoxinA (IncoA) injection for treatment of essential hand tremor. In essential tremor and Parkinson's disease tremor, administration of onabotulinumtoxinA via a fixed injection approach improves the tremor but a high percentage of patients (30–70%) develop moderate to severe hand weakness which has limited its use in clinical practice. Methods: This study was performed from July 2013 to July 2016 on 33 subjects. This is a double-blind, placebo-controlled, crossover trial injecting 80–120 units of IncoA into 8–14 hand and forearm muscles using a customized approach. The subjects were followed for 28 weeks. The treatment efficacy was evaluated by the Fahn Tolosa Marin tremor rating score and NIH genetic criteria for tremor severity at 4 and 8 weeks after each of the two sets of treatments. Hand strength was assessed by an ergometer. Results: There was statistically significant improvement in clinical rating score of tremor at 4 and 8 weeks following the IncoA injection. Conclusion: In this study, injection of IncoA treatment via a customized approach improved essential tremor on the clinical scales and patient's perception with a low occurrence of significant hand weakness.

Original languageEnglish (US)
Pages (from-to)65-69
Number of pages5
JournalParkinsonism and Related Disorders
Volume56
DOIs
StatePublished - Nov 1 2018

Fingerprint

Essential Tremor
Botulinum Toxins
Tremor
Hand
Placebos
Injections
Hand Strength
Forearm
Cross-Over Studies
Parkinson Disease
Therapeutics
Safety
Muscles
incobotulinumtoxinA

Keywords

  • Botulinum toxin
  • Clinical trial
  • Essential tremor
  • IncobotulinumtoxinA

ASJC Scopus subject areas

  • Neurology
  • Geriatrics and Gerontology
  • Clinical Neurology

Cite this

Botulinum toxin in essential hand tremor - A randomized double-blind placebo-controlled study with customized injection approach. / Mittal, Shivam Om; Machado, Duarte; Richardson, Diana; Dubey, Divyanshu; Jabbari, Bahman.

In: Parkinsonism and Related Disorders, Vol. 56, 01.11.2018, p. 65-69.

Research output: Contribution to journalArticle

@article{40624a6d54b04852874bd01da661de84,
title = "Botulinum toxin in essential hand tremor - A randomized double-blind placebo-controlled study with customized injection approach",
abstract = "Introduction: To evaluate the safety and efficacy of incobotulinumtoxinA (IncoA) injection for treatment of essential hand tremor. In essential tremor and Parkinson's disease tremor, administration of onabotulinumtoxinA via a fixed injection approach improves the tremor but a high percentage of patients (30–70{\%}) develop moderate to severe hand weakness which has limited its use in clinical practice. Methods: This study was performed from July 2013 to July 2016 on 33 subjects. This is a double-blind, placebo-controlled, crossover trial injecting 80–120 units of IncoA into 8–14 hand and forearm muscles using a customized approach. The subjects were followed for 28 weeks. The treatment efficacy was evaluated by the Fahn Tolosa Marin tremor rating score and NIH genetic criteria for tremor severity at 4 and 8 weeks after each of the two sets of treatments. Hand strength was assessed by an ergometer. Results: There was statistically significant improvement in clinical rating score of tremor at 4 and 8 weeks following the IncoA injection. Conclusion: In this study, injection of IncoA treatment via a customized approach improved essential tremor on the clinical scales and patient's perception with a low occurrence of significant hand weakness.",
keywords = "Botulinum toxin, Clinical trial, Essential tremor, IncobotulinumtoxinA",
author = "Mittal, {Shivam Om} and Duarte Machado and Diana Richardson and Divyanshu Dubey and Bahman Jabbari",
year = "2018",
month = "11",
day = "1",
doi = "10.1016/j.parkreldis.2018.06.019",
language = "English (US)",
volume = "56",
pages = "65--69",
journal = "Parkinsonism and Related Disorders",
issn = "1353-8020",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Botulinum toxin in essential hand tremor - A randomized double-blind placebo-controlled study with customized injection approach

AU - Mittal, Shivam Om

AU - Machado, Duarte

AU - Richardson, Diana

AU - Dubey, Divyanshu

AU - Jabbari, Bahman

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Introduction: To evaluate the safety and efficacy of incobotulinumtoxinA (IncoA) injection for treatment of essential hand tremor. In essential tremor and Parkinson's disease tremor, administration of onabotulinumtoxinA via a fixed injection approach improves the tremor but a high percentage of patients (30–70%) develop moderate to severe hand weakness which has limited its use in clinical practice. Methods: This study was performed from July 2013 to July 2016 on 33 subjects. This is a double-blind, placebo-controlled, crossover trial injecting 80–120 units of IncoA into 8–14 hand and forearm muscles using a customized approach. The subjects were followed for 28 weeks. The treatment efficacy was evaluated by the Fahn Tolosa Marin tremor rating score and NIH genetic criteria for tremor severity at 4 and 8 weeks after each of the two sets of treatments. Hand strength was assessed by an ergometer. Results: There was statistically significant improvement in clinical rating score of tremor at 4 and 8 weeks following the IncoA injection. Conclusion: In this study, injection of IncoA treatment via a customized approach improved essential tremor on the clinical scales and patient's perception with a low occurrence of significant hand weakness.

AB - Introduction: To evaluate the safety and efficacy of incobotulinumtoxinA (IncoA) injection for treatment of essential hand tremor. In essential tremor and Parkinson's disease tremor, administration of onabotulinumtoxinA via a fixed injection approach improves the tremor but a high percentage of patients (30–70%) develop moderate to severe hand weakness which has limited its use in clinical practice. Methods: This study was performed from July 2013 to July 2016 on 33 subjects. This is a double-blind, placebo-controlled, crossover trial injecting 80–120 units of IncoA into 8–14 hand and forearm muscles using a customized approach. The subjects were followed for 28 weeks. The treatment efficacy was evaluated by the Fahn Tolosa Marin tremor rating score and NIH genetic criteria for tremor severity at 4 and 8 weeks after each of the two sets of treatments. Hand strength was assessed by an ergometer. Results: There was statistically significant improvement in clinical rating score of tremor at 4 and 8 weeks following the IncoA injection. Conclusion: In this study, injection of IncoA treatment via a customized approach improved essential tremor on the clinical scales and patient's perception with a low occurrence of significant hand weakness.

KW - Botulinum toxin

KW - Clinical trial

KW - Essential tremor

KW - IncobotulinumtoxinA

UR - http://www.scopus.com/inward/record.url?scp=85048811753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048811753&partnerID=8YFLogxK

U2 - 10.1016/j.parkreldis.2018.06.019

DO - 10.1016/j.parkreldis.2018.06.019

M3 - Article

C2 - 29929813

AN - SCOPUS:85048811753

VL - 56

SP - 65

EP - 69

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

SN - 1353-8020

ER -